Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 17/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1518385 | 0.94 | REN (0.47) | RENKCNH2CYP3A4 | |
| SCHEMBL661553 | 0.89 | REN (0.38) | RENKCNH2CYP3A4NR1H4HSD11B1 | |
| SCHEMBL663545 | 0.85 | REN (0.47) | RENKCNH2CYP3A4 | |
| SCHEMBL1074250 | 0.84 | NR1H4 (0.42) | RENKCNH2CYP3A4NR1H4 | |
| SCHEMBL1074248 | 0.84 | NR1H4 (0.42) | RENKCNH2CYP3A4NR1H4 | |
| SCHEMBL1080226 | 0.83 | REN (0.51) | RENKCNH2CYP3A4 | |
| SCHEMBL664806 | 0.82 | HTR2A (0.37) | RENNR1H4HSD11B1HTR2A | |
| SCHEMBL1072359 | 0.80 | SLC6A4 (0.42) | RENKCNH2HTR2A | |
| SCHEMBL1751809 | 0.79 | REN (0.45) | RENKCNH2CYP3A4 | |
| SCHEMBL1072014 | 0.78 | REN (0.46) | RENKCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046293-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2012-02-23 | — | — | US | disclosed |
| US-8063105-B2 | Renin inhibitors | MERCK CANADA INC. (CA) | 2011-11-22 | — | — | US | disclosed |
| US-20090281103-A1 | Renin Inhibitors | MERCK CANADA INC. (CA) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046293-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | REN 1/4885KCNH2 1215/4885CYP3A4 774/4885 |
| US-20090281103-A1 | Renin Inhibitors | REN, ACE, AGT | REN 1/4885KCNH2 1536/4885CYP3A4 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.